[{"id":"0811eebd-2541-4c17-9f6e-9259710f1407","acronym":"TARGET-RT","url":"https://clinicaltrials.gov/study/NCT06796543","created_at":"2025-02-25T16:28:16.453Z","updated_at":"2025-02-25T16:28:16.453Z","phase":"","brief_title":"Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma","source_id_and_acronym":"NCT06796543 - TARGET-RT","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" EFS","pipe":"","alterations":" ","tags":["EFS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-01-29"},{"id":"870405e4-4dbb-479f-8821-12d08e25c8d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03942263","created_at":"2021-02-24T18:55:43.083Z","updated_at":"2024-07-02T16:35:58.816Z","phase":"","brief_title":"A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation","source_id_and_acronym":"NCT03942263","lead_sponsor":"Takeda","biomarkers":" ALK • EFS","pipe":"","alterations":" ","tags":["ALK • EFS"],"overall_status":"Completed","enrollment":" Enrollment 2000","initiation":"Initiation: 05/31/2019","start_date":" 05/31/2019","primary_txt":" Primary completion: 12/08/2022","primary_completion_date":" 12/08/2022","study_txt":" Completion: 12/08/2022","study_completion_date":" 12/08/2022","last_update_posted":"2022-12-20"},{"id":"6462b1e0-4b1c-4573-96bc-10fc5acd50bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00332202","created_at":"2021-06-23T22:52:36.234Z","updated_at":"2024-07-02T16:37:07.092Z","phase":"Phase 3","brief_title":"PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin","source_id_and_acronym":"NCT00332202","lead_sponsor":"Eli Lilly and Company","biomarkers":" PRKCB • EFS","pipe":"","alterations":" ","tags":["PRKCB • EFS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kinenza (enzastaurin)"],"overall_status":"Completed","enrollment":" Enrollment 758","initiation":"Initiation: 06/01/2006","start_date":" 06/01/2006","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 07/01/2013","study_completion_date":" 07/01/2013","last_update_posted":"2018-09-10"}]